A comparative study of five centrally acting drugs on the pharmacological treatment of obesity

International Journal of Obesity

Volumn 38, Issue 8, 2014, Pages 1097-1103

  Suplicy, H ^a   Boguszewski, C L ^a   Dos Santos, C M C ^a   Do Desterro De Figueiredo, M ^a   Cunha, D R ^a   Radominski, R ^a  

^a Parana Federal University   (Brazil)

Author keywords

anti obesity agents; clinical trial; weight loss drugs

Indexed keywords

AMFEPRAMONE; AMPHETAMINE DERIVATIVE; ANTIOBESITY AGENT; CYCLOBUTANE DERIVATIVE; FENPROPOREX; FLUOXETINE; MAZINDOL; SIBUTRAMINE;

ADULT; BODY MASS; BRAZIL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECTS; FEMALE; FOLLOW UP; HUMAN; LOW CALORY DIET; OBESITY; PROSPECTIVE STUDY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADULT; AMPHETAMINES; ANTI-OBESITY AGENTS; BODY MASS INDEX; BRAZIL; CYCLOBUTANES; DIET, REDUCING; DIETHYLPROPION; FEMALE; FLUOXETINE; FOLLOW-UP STUDIES; HUMANS; MAZINDOL; OBESITY; PROSPECTIVE STUDIES; QUESTIONNAIRES; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84905654349     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2013.225     Document Type: Article

References (40)

1. Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab 2004; 89: 2583-2589. (Pubitemid 38766335)
2. Berrington de, Gonzalez A, Hartge P, Cerhan JR, Flint AJ, Hannan L et al. Body-mass index and mortality among 1.46 million white adults. N Engl J Med 2010; 363: 2211-2219.
3. Unick JL, Beavers D, Jakicic JM, Kitabchi AE, Knowler WC, Wadden TA et al. Effectiveness of lifestyle interventions for individuals with severe obesity and type 2 diabetes: Results from the Look AHEAD trial. Diabetes Care 2011; 34: 2152-2157.
4. Sjoström L. Review of the key results from the Swedish Obese Subjects (SOS) trial: A prospective controlled intervention study of bariatric surgery. J Intern Med 2013; 273: 219-234.
5. Caterson ID, Finer N, Coutinho W, Van Gaal LF, Maggioni AP, Torp-Pedersen C et al. Maintained intentional weight loss reduces cardiovascular outcomes: Results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Diabetes Obes Metab 2012; 14: 523-530.
6. Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A et al. Long-Term persistence of hormonal adaptations to weight loss. N Engl J Med 2011; 365: 1597-1604.
7. Haddock CK, Poston WS, Dill PL, Foreyt JP, Ericsson M. Pharmacotherapy for obesity: A quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord 2002; 26: 262-273. (Pubitemid 34151206)
8. Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR et al. Meta-Analysis: Pharmacologic treatment of obesity. Ann Intern Med 2005; 142: 532-546.
9. Wilding JP. Treatment strategies for obesity. Obes Rev 2007; 8(Suppl 1): 137-144.
10. Bray GA. Lifestyle and pharmacological approaches to weight loss: Efficacy and safety. J Clin Endocrinol Metab 2008; 93(11 Suppl 1): S81-S88.
11. Colman E. Anorectics on trial: A half century of federal regulation of prescription appetite suppressants. Ann Intern Med 2005; 143: 380-385. (Pubitemid 41266610)
12. Borsini F, Bendotti C, Carli M, Poggesi E, Samanin R. The roles of brain noradrenaline and dopamine in the anorectic activity of diethylpropion in rats: A comparison with d-Amphetamine. Res Commun Chem Pathol Pharmacol 1979; 26: 3-11. (Pubitemid 10191311)
13. Santamaría A, Arias HR. Neurochemical and behavioral effects elicited by bupropion and diethylpropion in rats. Behav Brain Res 2010; 211: 132-139.
14. Cercato C, Roizenblatt VA, Leanca CC, Segal A, Lopes Filho AP et al. A randomized double-blind placebo-controlled study of the long-Term efficacy and safety of diethylpropion in the treatment of obese subjects. Int J Obes (Lond) 2009; 33: 857-865.
15. Cody JT, Valtier S, Stillman S. Amphetamine and fenproporex levels following multidose administration of fenproporex. J Anal Toxicol 1999; 23: 187-194. (Pubitemid 29244532)
16. Halpern A, Mancini MC. Treatment of obesity: An update on anti-obesity medications. Obes Rev 2003; 4: 25-42. (Pubitemid 36358194)
17. Inoue S. Clinical studies with mazindol. Obes Res 1995; 3(Suppl 4): 549S-552S.
18. Wellman PJ. Systemic mazindol reduces food intake in rats via suppression of meal size and meal number. J Psychopharmacol 2008; 22: 532-535.
19. Araújo JR, Martel F. Sibutramine effects on central mechanisms regulating energy homeostasis. Curr Neuropharmacol 2012; 10: 49-52.
20. Bray GA, Blackburn GL, Ferguson JM, Greenway FL, Jain AK, Mendel CM et al. Sibutramine produces dose-related weight loss. Obes Res 1999; 7: 189-198. (Pubitemid 129710577)
21. Aigner M, Treasure J, Kaye W, Kasper S. WFSBP Task Force on Eating Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of eating disorders. World J Biol Psychiatry 2011; 12: 400-443.
22. Goldstein DJ, Rampey Jr. AH, Enas GG, Potvin JH, Fludzinski LA, Levine LR. Fluoxetine: A randomized clinical trial in the treatment of obesity. Int J Obes Relat Metab Disord 1994; 18: 129-135. (Pubitemid 24087126)
23. Serretti A, Mandelli L. Antidepressants and body weight: A comprehensive review and meta-Analysis. J Clin Psychiatry 2010; 71: 1259-1272.
24. James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010; 363: 905-917.
25. Beck AT, Steer RA, Ball R, Ranieri W. Comparison of Beck Depression Inventories-IA and-II in psychiatric outpatients. J Pers Assess 1996; 67: 588-597. (Pubitemid 26382973)
26. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: Psychometric properties. J Consult Clin Psychol 1988; 56: 893-897. (Pubitemid 19008360)
27. Freitas S, Lopes CS, Coutinho W, Appolinario JC. Translation and adaptation into Portuguese of the Binge-Eating Scale. Rev Bras Psiquiatr 2001; 23: 215-220.
28. Ware Jr. JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473-483.
29. WHOQOL Group. The World Health Organization Quality of Life assessment (WHOQOL): Position paper from the World Health Organization. Soc Sci Med 1995; 41: 1403-1409.
30. Kolotkin RL, Head S, Hamilton M, Tse CK. Assessing impact of weight on quality of life. Obes Res 1995; 3: 49-56.
31. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419. (Pubitemid 15018832)
32. Lachin JM. Statistical considerations in the intent-To-Treat principle. Control Clin Trials 2000; 21: 167-189. (Pubitemid 30259147)
33. Coutinho W. The first decade of sibutramine and orlistat: A reappraisal of their expanding roles in the treatment of obesity and associated conditions. Arq Bras Endocrinol Metabol 2009; 53: 262-270.
34. Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): A randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 1341-1352.
35. Gray DS, Fujioka K, Devine W, Bray GA. A randomized double-blind clinical trial of fluoxetine in obese diabetics. Int J Obes Relat Metab Disord 1992; 16(Suppl 4): S67-S72. (Pubitemid 23088115)
36. Wise SD. Clinical studies with fluoxetine in obesity. Am J Clin Nutr 1992; 55(Suppl 1): 181S-184S.
37. Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010; 363: 245-256.
38. Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010; 376: 595-605.
39. Kim SH, Lee YM, Jee SH, Nam CM. Effect of sibutramine on weight loss and blood pressure: A meta-Analysis of controlled trials. Obes Res 2003; 11: 1116-1123.
40. Ioannides-Demos LL, Piccenna L, McNeil JJ. Pharmacotherapies for obesity: Past, current, and future therapies. J Obes 2011; 2011: 179674. .